These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35094788)

  • 1. How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?
    Berger ML; Crown W
    Value Health; 2022 Feb; 25(2):167-170. PubMed ID: 35094788
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project.
    Franklin JM; Pawar A; Martin D; Glynn RJ; Levenson M; Temple R; Schneeweiss S
    Clin Pharmacol Ther; 2020 Apr; 107(4):817-826. PubMed ID: 31541454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Banzi R
    Recenti Prog Med; 2019 Nov; 110(11):526-527. PubMed ID: 31808433
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Epidemiology Workshop 8--appraising a study on therapy.
    Yu IT; Tse SL
    Hong Kong Med J; 2012 Oct; 18(5):419-20. PubMed ID: 23018070
    [No Abstract]   [Full Text] [Related]  

  • 5. Examining the Use of Real-World Evidence in the Regulatory Process.
    Beaulieu-Jones BK; Finlayson SG; Yuan W; Altman RB; Kohane IS; Prasad V; Yu KH
    Clin Pharmacol Ther; 2020 Apr; 107(4):843-852. PubMed ID: 31562770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of the randomized controlled trial and its role in evidence-based decision making.
    Devereaux PJ; Yusuf S
    J Intern Med; 2003 Aug; 254(2):105-13. PubMed ID: 12859691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternatives to Randomised Controlled Trials for the Poor, the Impatient, and When Evaluating Emerging Technologies.
    Mani K; Björck M
    Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):598-599. PubMed ID: 30509892
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.
    Corrigan-Curay J; Sacks L; Woodcock J
    JAMA; 2018 Sep; 320(9):867-868. PubMed ID: 30105359
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evidence-based medicine: can we trust the results of well-designed randomized trials?].
    Maturana A; Benaglio C
    Rev Chil Pediatr; 2014 Oct; 85(5):533-8. PubMed ID: 25697428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs.
    Atkins D
    Med Care; 2007 Oct; 45(10 Supl 2):S16-22. PubMed ID: 17909376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [How to assess the quality of systematic review and meta-analysis].
    Zhang JH; Shang HC; Zhang BL
    Zhong Xi Yi Jie He Xue Bao; 2008 Apr; 6(4):337-40. PubMed ID: 18405597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to randomize, or 'Evidence-based medicine needs medicine-based evidence'.
    Concato J
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():6-12. PubMed ID: 22552974
    [No Abstract]   [Full Text] [Related]  

  • 14. Learning From Major Clinical Trials: Bending Without Breaking.
    Pfeffer MA
    Circulation; 2017 Dec; 136(23):2207-2209. PubMed ID: 29203564
    [No Abstract]   [Full Text] [Related]  

  • 15. The limitations of observation studies for decision making regarding drugs efficacy and safety.
    Gueyffier F; Cucherat M
    Therapie; 2019 Apr; 74(2):181-185. PubMed ID: 30514576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
    Manchikanti L; Datta S; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing Between Efficacy and Real-World Effectiveness: The Case for Thinking Beyond Classic Randomized Controlled Trial Design.
    Sites BD; Masaracchia MM; Davis M
    Reg Anesth Pain Med; 2017; 42(2):131-132. PubMed ID: 28207640
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise of pharmacoepidemiology in helping clinicians assess drug risk.
    Avorn J
    Circulation; 2013 Aug; 128(7):745-8. PubMed ID: 23940388
    [No Abstract]   [Full Text] [Related]  

  • 20. Consideration of medical research vs. scientific research.
    Pyle DE
    Med Hypotheses; 2005; 65(6):1199. PubMed ID: 16144744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.